Juha Ranti - UTU Research Portal - UTU Research Portal

Juha Ranti

- Doctoral Researcher,
Internal Medicine (Department of Clinical Medicine)

jtrant@utu.fi

Expertese

Ohjelmoituneen solukuoleman muokkaajat leukemioissa (2024)
- Duodecim
Kuusanmäki, Heikki; Ranti, Juha; Kontro, Mika
Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy (2024)
- European Journal of Clinical Microbiology and Infectious Diseases
Feuth Eeva, Nieminen Valtteri, Palomäki Antti, Ranti Juha, Sucksdorff Marcus, Finnilä Taru, Oksi Jarmo, Vuorinen Tytti, Feuth Thijs
Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010-2020: A retrospective analysis of electronic health records (2024)
- European Journal of Haematology
Ranti, Juha; Pudas, Hanna; Ranta, Martta; Tuominen, Samuli; Uusi-Rauva, Kristiina; Lammela, Johanna
Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation - A retrospective single-center study (2022)
- Transplant Infectious Disease
Ranti Juha, Perkonoja Katariina, Kauko Tommi, Korhonen Riku
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial (2022)
- Lancet Oncology
Kater Arnon P., Levin Mark-David, Dubois Julie, Kersting Sabina, Enggaard Lisbeth, Veldhuis Gerrit J., Mous Rogier, Mellink Clemens H.M., van der Kevie-Kersemaekers Anne-Marie F., Dobber Johan A., Poulsen Christian B., Frederiksen Henrik, Janssens Ann, Schjødt Ida, Dompeling Ellen C., Ranti Juha, Brieghel Christian, Mattsson Mattias, Bellido Mar, Tran Hoa T.T., Nasserinejad Kazem, Niemann Carsten U.
Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center (2021)
- eJHaem : eJournal of Haematology
Ranti Juha, Perkonoja Katariina, Kauko Tommi, Loponen Heidi, Joensuu Emmi I., Järvinen Tiina M.
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (2021)
- Blood
Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Bellido M, Mattsson M, Nasserinejad K, Tran HTT, Kater AP
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance >= 30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations (2020)
- BMJ Open
Levin Mark-David, Kater Arnon P, Mattsson Mattias, Kersting Sabina, Ranti Juha, Tran Hoa Thi Tuyet, Nasserinejad Kazem, Niemann Carsten Utoft
Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT (2018)
- PLoS ONE
Juha Ranti, Samu Kurki, Urpu Salmenniemi, Mervi Putkonen, Soile Salomäki, Maija Itälä-Remes